NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
The main methods of NADH powder preparation from worldwide NADH manufacturers include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
1、“Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NADH powder
3、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
4、Provide one-stop product solution customization service
1.Improved energy levels
Not only does NADH act as an important coenzyme in aerobic respiration, the [H] of NADH also carries a large amount of energy. Studies have demonstrated that extracellular use of NADH promotes increased intracellular ATP levels, suggesting that NADH penetrates cell membranes and elevates intracellular energy levels. On a macro level, exogenous supplementation of NADH helps to restore energy and enhance appetite. The increase in energy levels in the brain also helps to improve mental performance and sleep quality. NADH has been used overseas to improve chronic fatigue syndrome, increase exercise endurance, jet lag and other areas.
2.Cellular protection
NADH is a strong antioxidant that naturally occurs in cells and reacts with free radicals to inhibit lipid peroxidation, protecting mitochondrial membranes and mitochondrial function. It has been found that NADH can reduce oxidative stress in cells caused by various factors such as radiation, drugs, toxic substances, strenuous exercise and ischemia, thus protecting vascular endothelial cells, hepatocytes, cardiomyocytes, fibroblasts and neurons. Therefore, injectable or oral NADH is used clinically to improve cardiovascular and cerebrovascular diseases, and as an adjunct to cancer radiotherapy. Topical NADH has been shown to be effective in the treatment of rosacea and contact dermatitis.
3.Promotion of neurotransmitter production
Studies have shown that NADH significantly promotes the production of the neurotransmitter dopamine, a chemical signal that is essential for short-term memory, involuntary movements, muscle tone and spontaneous physical responses. It also mediates the release of growth hormone and determines muscle movement. Without sufficient dopamine, muscles become stiff. Parkinson's disease, for example, is caused in part by a disruption of dopamine synthesis in brain cells. Preliminary clinical data suggest that NADH can help improve the symptoms of Parkinson's disease [9]. NADH also promotes the biosynthesis of norepinephrine and serotonin, showing good potential for use in the relief of depression and Alzheimer's disease.
1. Prevention and treatment of viral-induced inflammatory storms
Scientists have found after extensive research that neo-coronavirus has a mechanism similar to SARS virus to activate inflammatory vesicles NLRP3. and the activation of NLRP3 produces more inflammatory factors, generating excessive inflammation and thus triggering a deadly cytokine storm. This problem can be well addressed by NAD+, which inhibits the activity of NF-κB inflammatory pathway and NLRP3 inflammasome by increasing the activity of sirtuins (SIRT1, SIRT2 and SIRT3), thus preventing cytokine storm caused by excessive inflammation. Therefore, Sinclair and other scientists believe that increasing the concentration of NAD+ may play an important role in the prevention and treatment of neocoronavirus and other viral infections.
2. Restoration of virus-induced metabolic disorders
NAD+ is an essential coenzyme for many cellular energy metabolic pathways, present in every cell of the body, involved in thousands of reactions, and an important player in maintaining cellular viability. In the COVID-19 infection model, NAD+ and NMN supplementation was found to be effective in alleviating cell death and protecting the lung.
The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes
First, inspect the factory. After some screening, NADH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NADH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NADH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction On January 9, 2024, the expert team of selection organizing committee from Deloitte visited BONTAC, and presented the trophy of “China Life Sciences & Healthcare Rising Star” to BONTAC on site. By virtue of its unique and innovative technology in the field of coenzymes, professional R&D team with rich experience, and excellent performance in the industry of biosynthesis, BONTAC has stood out from the crowd and won the award of "Deloitte China Life Sciences & Healthcare Rising Star". 2. 2023 Deloitte China Life Sciences & Healthcare Rising Star Since the launch of “Deloitte China Life Sciences & Healthcare Rising Star” campaign by the end of June 2023, extensive attention has been attracted by the Chinese medicine and health industry. Following verification by site visit of the enterprises, 50 enterprises with prominent comprehensive strength are finally determined to be eligible, which are subjected to rigorous review of multiple dimensions such as financial asset valuation, founding team, technical innovation, market prospect, industrial rank, etc. The awarded enterprises in this selection campaign encompass the advanced enterprise in the niche areas of life sciences and healthcare, who comprehensively display their multiple innovation achievements in the field of life sciences and healthcare. The “Deloitte China Life Sciences & Healthcare Rising Star” selection campaign is a key subproject of Deloitt on the selection project of high-tech and fast-growing enterprises, aiming to recognize and award the outstanding enterprises who take the lead in their niche areas of life sciences and healthcare and have great growth potential. 3. The candidate enterprises must meet the the following criteria: * Business headquartered within China Mainland, Hong Kong or Macao. * Own leading technology and viable business models. * Have extensive growth potential with a leading position in their niche segments. 4. Current situation on Chinese medicine and health industry The technical innovation and product quality in Chinese medicine and health industry have continuously improved, which is driven by healthcare reform policies, emerging technologies and capital markets. In China, independent innovation has penetrated into all tracks of the major health industry, which greatly promotes the research and development of domestically produced innovative medicines and medical technologies. Substantial promising innovative enterprises has emerged and gradually gained recognition in the global market, ranking among the first echelon of global technological innovation. 5. About BONTAC BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BONTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. BONTAC adheres to independent innovation, with more than 160 invention patents. In the future, BONTAC will adhere to the innovation-driven concept, continue to increase investment in research and development, dig into the field of synthetic biology, and commit to developing more high-quality raw material products. At the same time, BONTAC will actively expand the international market, and work with global partners to promote the prosperous development of synthetic biology industry. In this era full of challenges and opportunities, BONTAC is confident to make greater contributions to the cause of human health.
Recently, a piece of good news came from the Japan Patent Office (one of the largest patent offices in the world) across the ocean to Shenzhen. The patent for "A STABLE NICOTINAMIDE RIBOSE COMPOSITION AND ITS PREPARATION METHOD" applied by Bontac was approved and issued a certificate. This invention patent is of great significance to the stability of Bontac coenzyme series products. This is another new recently patent obtained by Bontac after accumulating more than 150 patent applications. Such impressive achievements in scientific research are undoubtedly the best commendation for the innovative spirit of Bontac Biotech. Invention Title: A STABLE NICOTINAMIDE RIBOSE COMPOSITION AND ITS PREPARATION METHOD Technical advantages: Industrial artificial preparation of nicotinamide ribosehave made considerable progress to prepare relatively pure nicotinamide ribose at a lower cost. However, the monomer will become a viscous solid within a few seconds or minutes under ambient temperature and humidity as nicotinamide ribose is very easy to absorb moisture, and will disintegrate into oil within a few hours. In order to keep nicotinamide ribose as a dry solid, it needs to be stored in an absolutely dry environment, or frozen stored at about -20°C, which severely restricts the commercial application and promotion of nicotinamide ribose. Therefore, the development of stable nicotinamide ribose products has become a major problem that needs to be solved urgently. The purpose of the present invention is to solve the technical problem that the nicotinamide ribose monomer mentioned in the above background art is difficult to preserve and cannot be promoted and applied because it is very easy to absorb moisture and decompose. The invention provides a nicotinamide ribose composition with stable properties, easy storage, transportation and use. Only by continuously innovating technology can we adapt to the new opportunities in the new era, "respond to all changes" before new challenges, and produce a qualitative leap based on quantity. In the current favorable situation, Bontac Biotech's innovation plan is still non-stop, focusing on the overall market direction, paying attention to every link, solving every subtle problem, and writing Bontac's legend with active innovation. At this stage, Bontac Bio will continue to build a better R&D team, increase investment in scientific research, create better products for our customers, and empower greater value.
Introduction Targeting the autophagy-NAD axis has been reported be a viable therapeutic strategy for Niemann-Pick type C1 (NPC1) disease. The study suggests that both pharmacological rescue of autophagy deficiency and supplementation of NAD precursors can restore NAD+ level, improve the viability of fibroblasts in NPC1 patients, and induce pluripotent stem cell (iPSC)-derived cortical neurons. About NPC1 disease Niemann-Pick disease, a hereditary chronic neurologic disorder, is categorized into three types, with NPC1 occurring in more different populations. NPC1 disease, an autosomal recessive disorder, is characterized by an enlarged spleen, neurological dysfunctions, and the accumulation of lipids such as sphingolipids and cholesterol. The disease is most commonly caused by mutations in the NPC1 gene which encodes a cholesterol transporter on the lysosomal membrane. Targeting the autophagy-NAD axis: a promising approach for NPC1 disease The loss of NPC1 function leads to impaired autophagy/mitophagy, resulting in NAD+ depletion, mitochondrial depolarisation, and apoptotic cell death. However, the use of autophagy inducers (celecoxib or memantine) and NAD precursors has shown promise in ameliorating the phenotypes observed in mouse and human NPC1 model cells. Notably, NAD precursor supplementation acts downstream of autophagy dysfunction. Specifically, this supplementation promotes the viability of Npc1-/- MEFs and restores the apoptotic cell death in Npc1-/- cells, but exhibits no or mild upregulation of autophagy function in mouse embryonic fibroblasts (MEFs) and primary fibroblasts. However, autophagy activators not only rescue NAD depletion and cell death in Npc1-/- MEFs, but also restore autophagic flux and mitophagy deficit. Targeting the autophagy-NAD axis can promote the survival of NPC1 patient-derived primary fibroblasts and protect against cell death of NPC1 patient iPSC-derived cortical neurons. Strikingly, boosting NAD+ level is believed to improve mitochondrial function and ATP generation, potentially replenishing lysosomal degradation capacity and restoring autophagic function in NPC1-mutant neurons. NPC1 patient-derived primary fibroblasts NPC1 patient iPSC-derived cortical neurons Conclusion Both autophagy inducers and NAD precursors are effective in ameliorating NPC1 disease, and combining the two may complement their strengths and maximize their effectiveness, opening new insights into the neurodegenerative conditions associated with autophagy and NAD+ defects. Reference Kataura T, Sedlackova L, Sun C, et al. Targeting the autophagy-NAD axis protects against cell death in Niemann-Pick type C1 disease models. Cell Death Dis. 2024;15(5):382. Published 2024 May 31. doi:10.1038/s41419-024-06770-y BONTAC NAD BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR). There are various types of NAD to be selected, encompassing NAD ER Grade (endoxin removal), NAD Grade I (IVD/dietary supplement/cosmetics raw powder), NAD Grade II (API/intermediates) and NAD Grade IV (if any higher requirement on the solubility), which can be provided in the form of lyophilized powder or crystalline powder. The purity of BONTAC NAD can reach above 98%. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible in any way for any claims, damages, losses, expenses or costs arising directly or indirectly from your reliance on the information and material on this website.